GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated October 10, 2025, serves as a transaction notification for the month of October 2025. The document discloses share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to specific share transactions:
- Instrument: Ordinary shares of 31 1/2 pence each (ISIN: GB00BN7SWP63).
- Transaction Price: £16.4083 per share for all reported transactions.
- Total Volume: 116 Ordinary Shares acquired across eight executives.
- Transaction Date: October 9, 2025.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly details routine equity compensation awards.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of insider share acquisitions.
Investor Verification Checklist
- Verify the total number of shares acquired by each executive (ranging from 14 to 16 shares per individual).
- Confirm the transaction price of £16.4083 aligns with the market price on October 9, 2025.
- Note that all transactions were classified as acquisitions under the Share Reward Plan, consisting of partnership and matching shares.
- Identify the specific executives involved: Emma Walmsley (CEO), Julie Brown (CFO), James Ford (SVP Legal), Sally Jackson (SVP Communications), David Redfern (President Corporate Development), Regis Simard (President Supply Chain), Philip Thomson (President Global Affairs), Deborah Waterhouse (CEO ViiV), and Victoria Whyte (Company Secretary).